NEW YORK, July 29, 2026 — U.S. equity markets traded higher ahead of the opening bell as investors digested news from the Centers for Medicare & Medicaid Services (CMS) regarding the planned discontinuation of temporary prescription drug plan (PDP) subsidies after 2026. The program, which provided $3.6 billion in assistance this year, has helped keep premiums lower for beneficiaries, but its expiration will shift significant pricing risk back to insurers starting next year.
2027 Bids and Premiums Show Rising Costs
According to initial CMS data, the national average monthly bid for 2027 stands at $296.05, representing a 23.7% increase from 2026 levels. The standard beneficiary premium will rise 6% to $41.33 per month. While ongoing federal subsidies still account for a large portion of the increased bid values, the temporary PDP-specific buffer—estimated at $16 per member per month in 2026 by KFF—will no longer be available. Medicare Advantage prescription drug plans (MA-PDs) previously applied a $53 monthly offset sourced from rebates, and that gap may widen further.
Enrollment Dynamics Shift Toward Medicare Advantage
The average 2026 PDP premium was $36, compared with just $8 for MA-PDs—a 4.5-fold difference that already encourages consumers to compare plans. Rising PDP prices could accelerate the shift toward Medicare Advantage, putting additional pressure on stand-alone PDP providers. KFF enrollment data highlights significant differences in PDP exposure versus MA-PD offsets across major insurers.
Centene Faces Heightened Sensitivity
Centene (NYSE: CNC) holds the largest stand-alone PDP market share at 35%, representing 8.7 million enrollees—an 11% increase from the prior year. This leads its closest publicly traded competitor by 19 percentage points. However, unlike UnitedHealth, Humana, and CVS Health, Centene does not hold a top-three position in the MA-PD segment, making its member retention more dependent on PDP pricing. The company's annual report notes that a large portion of its PDP membership comes from automatic assignments, which require bids to remain under regional benchmarks. All 34 regional benchmarks were cleared by its 2026 bids, but Centene warned that failure to maintain benchmark status could significantly impact revenue.
Competitors Show Mixed Exposure
Humana (NYSE: HUM) saw its PDP enrollment surge 61% after lowering premiums in numerous regions, and its 20% MA-PD share provides some offsetting strength. UnitedHealth (NYSE: UNH) leads with the largest MA-PD offset at 26% market share, while CVS Health (NYSE: CVS) holds a more balanced 16% PDP and 10% MA-PD position. The subsidy rollback intensifies the dilemma for Centene: either keep premiums low to maintain enrollment, or safeguard margins at the risk of losing members.
Regulatory and Industry Reactions
CMS Administrator Mehmet Oz stated that “premiums will go up by less than $10 for most Medicare recipients,” though some may see lower amounts. KFF’s Juliette Cubanski cautioned that certain individuals could face “relatively steep” increases. Industry group AHIP reported that insurers were still assessing the decision on Tuesday night. Updated premiums and available plans are expected in mid-to-late September, with the full earnings impact yet to be determined.
Key Data Points and Outlook
- Centene (CNC): 35% PDP market share, 8.7 million enrollees, 11% enrollment growth, no top-three MA-PD position.
- CVS Health (CVS): 16% PDP share, 10% MA-PD share.
- UnitedHealth (UNH): 15% PDP share, slight growth, 26% MA-PD share.
- Humana (HUM): 3.7 million PDP enrollees, 61% enrollment growth, 20% MA-PD share.
The primary threat to the thesis comes from how insurers act. Companies could choose to operate with slimmer margins or adjust products to reduce customer turnover. Critical data on county-level premiums and benchmark standings is still unavailable. September pricing files will distinguish between a margin squeeze and an enrollment transfer, with Centene’s regional benchmark standings offering the first clear indication.
